Biomedical subjects

L Tapia-Arancibia

Publications and source records attributed to L Tapia-Arancibia.

At least 19 recordsLinked to original sources

PubMed1992

NMDA receptor activation stimulates phospholipase A2 and somatostatin release from rat cortical neurons in primary cultures.

We have recently shown that glutamate exerts a stimulatory action on somatostatin secretion in cortical neurons essentially through NMDA receptor sites. Here, we investigated whether arachidonic acid release could be modified after NMDA receptor activation in cortical neurons in primary culture. We also studied whether pharmacological manipulation of phospholipase A2 could modify somatostatin release. We found that both glutamate and NMDA (N-methyl-D-aspartate) stimulated [3H]arachidonic acid release. NMDA-evoked arachidonic acid release was inhibited by MK-801 and TCP (two NMDA receptor-type antagonists), or by mepacrine, an inhibitor of phospholipase A2. NMDA-induced somatostatin release was inhibited by MK-801, mepacrine and by another phospholipase A2 inhibitor, p-bromophenacylbromide (pBPB). However, responses to NMDA were unaffected by H7, NDGA (nordihydroguaiaretic acid), indomethacin or by RHC 80267 (inhibitors of protein kinase C, lipooxygenase, cyclooxygenase and diacylglycerol lipase, respectively). Mepacrine (greater than or equal to 100 microM) decreased NMDA-stimulated phosphatidylinositol (PI) hydrolysis and at higher concentrations (250 microM) was also able to inhibit basal release whereas pBPB had no effect in the range of concentrations tested. Neomycin (which inhibits phosphatidylinositol metabolism by binding strongly and selectively to inositol phospholipids) reduced by 30% the NMDA-stimulated somatostatin release, although chronic treatment of neurons with the phorbol ester 12-myristate, 13-acetate (PMA) had no effect on this response. Melittin, an activator of phospholipase A2, was able to stimulate both arachidonic acid release and somatostatin secretion. High-performance liquid chromatography (HPLC) analysis of tritiated metabolites released from cortical neurons under basal or NMDA-stimulated conditions revealed that [3H]arachidonic acid was the only metabolite detectable. Furthermore, external addition of arachidonic acid increased somatostatin secretion. Our results show a correlation between the two parameters studied.

Animals↗

PubMed1992

Gamma-aminobutyric acid-glutamate interaction in the control of somatostatin release from hypothalamic neurons in primary culture: in vivo corroboration.

Recent studies have provided new data on the neuroendocrine role of glutamate (the major excitatory neurotransmitter) on somatostatin release. The neuroendocrine role of gamma-aminobutyric acid (GABA) (the major inhibitory neurotransmitter) on this same secretion, is also well established. Our objective was thus to investigate whether GABA and glutamate, which have opposite neurotransmission signals, could interact in the control of hypothalamic somatostatin release. Pharmacological manipulations of the two types of receptors were performed in vitro on primary cultures of hypothalamic neurons secreting somatostatin. We found that tonic release of somatostatin was reduced by 76% in the presence of tetrodotoxin (TTX) and was regulated by endogenous secretion of glutamate and GABA. CGS 19755, a highly selective N-methyl-D-aspartate (NMDA) receptor antagonist, significantly reduced tonic somatostatin secretion whereas it was strongly increased by picrotoxin and bicuculline, two GABAA antagonists. When CGS 19755 was applied with picrotoxin, somatostatin release was the same as levels obtained in the control group with TTX. GABA reduced tonic somatostatin release (in the presence or absence of TTX), and glutamate-stimulated secretion in a dose-dependent manner. Picrotoxin stimulation of tonic somatostatin release was additive with that obtained after glutamate stimulation and was also dose-dependent. This interaction was also studied in vivo in unanesthetized rats bearing a push-pull cannula stereotaxically implanted into the median eminence. Ip injected CGS 19755 (an antagonist that can freely permeate the blood-brain barrier) completely blocked the peak secretion of somatostatin observed after ip picrotoxin administration, whereas there was no significant effect when it was injected alone. These findings corroborated our in vitro data and allow us to postulate that GABA and glutamate interact in the control of somatostatin.

Animals↗

PubMed1990

Pharmacological properties of the NMDA receptor involved in somatostatin release from cortical neurons.

Glutamate increases somatostatin release from cultured cerebral cortical neurons, presumably through a N-methyl-D-aspartate (NMDA) receptor type. We report here that the NMDA response was potentiated by D-serine (10 microM) and that this potentiation was blocked by kynurenic acid (4-hydroxyquinoline-2-carboxylic acid; KYN). A higher concentration of D-serine (100 microM) reduced the antagonistic effect of KYN. Furthermore, the NMDA response exhibited another characteristic property of the NMDA receptor: it was decreased by low concentrations of Zn2+ (50 microM). In contrast, Zn2+ slightly but significantly potentiated the quisqualate (QA)- and kainate (KA)-induced responses.

Animals↗

PubMed1989

Physiological evidence for alpha 1-adrenergic facilitatory control of the cold-induced TRH release in the rat, obtained by push-pull cannulation of the median eminence.

The alpha-adrenergic antagonists phentolamine and prazosin were administered to male rats to explore their effects on cold-induced TRH release, measured by a chronic push-pull cannula stereotaxically implanted in the median eminence (ME). Phentolamine was given either i.p. (24 or 40 mg/kg), or locally (10(-5) M) in the ME, whereas prazosin was only applied locally (10(-5) M). Phentolamine significantly decreased the cold response (5 +/- 1 pg/15 min vs 21 +/- 5 pg/15 min; P less than 0.02), whatever the administration mode. Moreover, the blocking effect of prazosin directly perfused into the ME (11 +/- 3 pg/15 min vs 26 +/- 9 pg/15 min; P less than 0.05), indicates the specific involvement of alpha 1-adrenergic receptors in the cold-induced TRH response, and points to the ME as a possible site of facilitatory adrenergic control.

Animals↗

PubMed1989

Somatostatin inhibition of VIP-induced somatostatin release, cyclic AMP accumulation and 45Ca2+ uptake in diencephalic cells.

The effect of somatostatin (SRIF) on VIP induction of SRIF secretion, cyclic AMP accumulation and 45Ca2+ influx was investigated in cultured diencephalic cells. [D-Trp8]SRIF suppressed VIP-stimulated SRIF release and decreased VIP-stimulated cyclic AMP accumulation in a dose-dependent manner. SRIF-14 blocked basal and VIP-stimulated 45Ca2+ entry into cells. The data suggest that the inhibitory effect of SRIF on VIP-induced SRIF release is partly due to a decrease in Ca2+ entry into cells.

Animals↗

PubMed1989

Ontogeny of the metencephalic, mesencephalic and diencephalic content of catecholamines as measured by high performance liquid chromatography with electrochemical detection.

Developmental changes in norepinephrine (NE), dopamine (DA) and epinephrine (E) contents of the rat metencephalon, mesencephalon and diencephalon, have been measured by high performance liquid chromatography with electrochemical detection, from fetal stages (E15 or E17 to E21) to postnatal days (P0 to P30) and compared to the adult levels. The data show a biphasic pattern in NE changes of the three brain areas, with a first increase in the late prenatal period, followed by a further development from P0 to P18, thus reaching the adult levels. A similar pattern of development is found for the mesencephalic and diencephalic DA contents. The E levels of the diencephalon are very low in comparison to the NE and DA concentrations, but present a gradual increase from E17 to P18. The results correlate with the development of catecholamine systems in brain area as measured by other methodological approaches.

Animals↗

PubMed1989

Actions of excitatory amino acids on somatostatin release from cortical neurons in primary cultures.

L-Glutamate, N-methyl-D-aspartic acid (NMDA), quisqualate, and kainate were found to increase endogenous somatostatin release from primary cultures of rat cortical neurons in a dose-dependent manner. The rank order of potency calculated from the dose-response curves was quisqualate greater than glutamate = NMDA greater than kainate, with EC50 values of 0.4, 20, and 40 microM, respectively. Alanine, glutamine, and glycine did not modify the release of somatostatin. The stimulation of somatostatin release elicited by L-glutamate was Ca2+ dependent, was decreased by Mg2+, and was blocked by DL-amino-5-phosphonovaleric acid (APV) and thienylphencyclidine (TCP), two specific antagonists of NMDA receptors. The NMDA stimulatory effect was strongly inhibited by APV in a competitive manner (IC50 = 50 microM) and by TCP in a noncompetitive manner (IC50 = 90 nM). The release of somatostatin induced by the excitatory amino acid agonists was not blocked by tetrodotoxin (1 microM), a result suggesting that tetrodotoxin-sensitive, sodium-dependent action potentials are not involved in the effect. Somatostatin release in response to NMDA was potentiated by glycine, but the inhibitory strychnine-sensitive glycine receptor did not appear to be involved. Our data suggest that glutamate exerts its stimulatory action on somatostatin release essentially through an NMDA receptor subtype.

Alanine↗

PubMed1989

Calcium dependence of somatostatin (SRIF) release and cyclic AMP levels in cultured diencephalic neurons.

Calmodulin has been reported to be involved in the Ca2+-dependent hypothalamus in vitro. The present experiments were undertaken to determine whether at an early stage of development (in diencephalic primary cultures secreting SRIF, on the 11th day) the activation of a Ca2+-calmodulin kinase system is also involved in the release of the peptide. Since a calmodulin-dependent adenylate cyclase activity has been detected in the brain, we measured intracellular cyclic AMP accumulation as an additional parameter of calmodulin activity. SRIF release and cyclic AMP accumulation were stimulated by K+ (56 mM) and by the Ca2+ ionophores ionomycin (0.5 microM) and A 23187 (in a dose-dependent manner). Incubation of cells in Ca2+-free Locke medium or in the presence of Co2+ (1 mM) completely blocked ionophore-induced SRIF release and cyclic AMP accumulation. Three calmodulin antagonists (calmidazolium, W-7, and chlorpromazine) and two blockers of calmodulin-dependent kinase (phenytoin and diazepam) were tested on evoked-SRIF release and cyclic AMP formation. Neither W-7 nor calmidazolium modified A 23187-induced SRIF release at any dose tested, although they inhibited, in a dose-dependent manner, the stimulatory effect of the Ca2+ ionophore on cyclic AMP accumulation.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗

PubMed1988

Adenylate cyclase activation is not sufficient to stimulate somatostatin release from dispersed cerebral cortical and diencephalic cells in glia-free cultures.

Under conditions in which vasoactive intestinal peptide (VIP) induces somatostatin release from cortical and diencephalic neuronal cultures, VIP causes large increases in intracellular cyclic AMP. Both the release of somatostatin and the increase in cyclic AMP elicited by VIP require exogenous calcium, can be blocked by cobalt ion, and can be qualitatively mimicked by depolarizating concentrations of exogenous potassium ion. Direct activation of adenylate cyclase by forskolin causes large increases in cyclic AMP content but does not induce somatostatin release. In the absence of VIP, the calcium ionophore, ionomycin, and the phorbol ester, phorbol 12-myristate-13-acetate, also stimulate somatostatin release. These results indicate that VIP-stimulation of cyclic AMP formation and VIP-stimulation of somatostatin release are calcium-dependent and that the two phenomena are dissociatable. Cyclic AMP formation is not a necessary condition for VIP-induced somatostatin release. Nucleotide formation may be a sufficient condition for release or, possibly in association with calcium influx, it may be an event unrelated to the release process.

1-Methyl-3-isobutylxanthine↗

PubMed1988

The presence of non-neuronal cells influences somatostatin release from cultured cerebral cortical cells.

We examined the effect of non-neuronal cells on somatostatin release from cultured cerebral cortical cells. Three culture models were used: (1) neuron-enriched cultures obtained from cortex of 17-day-old rat embryos and exposed to 10 microM cytosine arabinoside (Ara C) for 48 h between days 3 and 5 after plating; (2) whole cell cultures obtained by using the same protocol but untreated with Ara C; (3) glial primary cultures obtained from newborn rats. We studied: (i) the cellular composition of the cultures by using two astroglial markers: vimentin and glial fibrillary acidic protein (GFAP); (ii) the spontaneous and forskolin-stimulated somatostatin release. In 8-day-old cultures morphological data revealed that Ara C treatment reduced glial cells to 6%. At 7 and 10 days of culture somatostatin spontaneously released from Ara C-treated cells was higher than that measured from untreated cells. On the 17th day of culture, neuron-enriched cultures contained a lower amount of somatostatin than whole cell cultures. Forskolin elicited a dose-dependent release of somatostatin from whole cell cultures, but had no effect on neuron-enriched cultures. Astroglial released media (ARM) from glial primary cultures exposed to forskolin for 20 min induced somatostatin release from neuron-enriched cultures. HPLC analysis of endogenous amino acids of ARM showed that glutamate, glutamine, glycine and alanine were significantly increased after forskolin stimulation. Our results suggest a functional interaction between glial cells and neurons secreting somatostatin.

Amino Acids↗

PubMed1988

Activators of protein kinase C enhance cyclic AMP accumulation in cerebral cortical and diencephalic neurons in primary culture.

The effects of the active phorbol ester 12-myristate, 13-acetate (PMA), the inactive ester 4 alpha-phorbol 12,13-didecanoate (4 alpha-PDD), and the synthetic diacylglycerol 1-oleoyl-2-acetyl-glycerol (OAG) on cyclic AMP production were examined in rat cerebral cortical and diencephalic cells. With the aid of a prelabeling technique for measuring cyclic AMP accumulation in the cells, it was found that neither PMA nor OAG significantly increased cyclic AMP formation in either type of cell. In contrast, PMA enhanced the cyclic AMP response to vasoactive intestinal peptide (VIP) and forskolin in cerebral cortical and diencephalic cells, whereas 4 alpha-PDD was inactive. A 15-min preincubation was used to obtain maximal enhancement. The concentration dependence of PMA on VIP-stimulated cyclic AMP accumulation was determined in cortical cells (EC50 = 6.2 x 10(-8) M). OAG was also able to potentiate VIP-induced cyclic AMP formation in cortical and diencephalic cells. However, its potentiating effect was weaker than that observed with PMA treatment. The data show, at an early stage of development (primary cultures, 8-10 days), a modulation of VIP- or forskolin-cyclic AMP response by the activators of protein kinase C, i.e., PMA and OAG, in two different structures of the central nervous system: the cerebral cortex and the diencephalon. To our knowledge, this is the first demonstration of such a potentiation within the diencephalon.

Animals↗

PubMed1988

Glutamate stimulates somatostatin release from diencephalic neurons in primary culture.

The action of excitatory amino acid agonists on endogenous somatostatin release was examined in primary cultures of rat diencephalic neurons. Increasing concentrations of glutamate stimulated somatostatin release in a dose-dependent manner. Since this effect was decreased by Mg2+, all experiments were performed in Mg2+-free media. We found that excitatory amino acid agonists evoked somatostatin release in the following order of potency: quisqualate greater than glutamate = N-methyl-D-aspartate (NMDA) greater than kainate, as calculated from the dose-response curves. The increase in somatostatin release elicited by glutamate or NMDA was selectively antagonized by DL-2-amino-5-phosphonovaleric acid and by thyenyl-phencyclidine, two specific antagonists of NMDA receptors. The NMDA effect was strongly inhibited: in a competitive manner by APV and in a noncompetitive manner by TCP with IC50 of 90 microM and 0.2 microM, respectively. Glutamate-induced somatostatin release was not blocked by tetrodotoxin (1 microM) suggesting that tetrodotoxin-sensitive sodium-dependent action potentials are not involved in this effect. Our data suggest the presence of functionally active excitatory amino acid receptors in somatostatinergic neurons. Glutamate seems to exert its stimulatory action on somatostatin release essentially through NMDA type receptor sites.

2-Amino-5-phosphonovalerate↗

PubMed1988

Effect of norfloxacin, a new quinolone, on GABA modulation of TRH-induced TSH release from perifused rat pituitaries.

The effect of the quinolone norfloxacin, a new antibacterial agent that is thought to induce convulsions in patients by inhibiting the binding of GABA, was tested on the two kinds of GABA A modulation of fTRH-induced TSH release from perifused rat pituitaries. Norfloxacin (50 mumol/l) was found to reverse the inhibitory effect of GABA (100 nmol/l) on the TSH release induced by TRH (10 nmol/l). The ratio of induced over spontaneous release was 0.79 +/- 0.05 in the presence of GABA, and 2.32 +/- 0.18 when norfloxacin was added 15 min before GABA vs 2.59 +/- 0.09 in the control response to TRH. Norfloxacin was also able to reverse the potentiating effect of GABA (10 nmol/l): the TSH response was 6.56 +/- 0.94 in the presence of GABA alone vs 2.92 +/- 0.35 with norfloxacin plus GABA. Norfloxacin was also able to reverse the potentiation induced by isoguvacine, a specific GABA A agonist (6.15 +/- 1.14 in the presence of isoguvacine vs 2.99 +/- 0.54 with norfloxacin plus isoguvacine). Our results suggest that norfloxacin may antagonize the effect of GABA via the two classes of GABA A receptor sites which differ in affinity and are responsible for the dual effect of GABA on the TRH-induced TSH secretion.

Animals↗

PubMed1988

Decrease of hypothalamic TRH levels but not plasmatic TSH levels after ablation of submandibular salivary glands in the rat.

Indirect relationships are thought to exist between submandibular salivary glands (SSG) and the central nervous system (CNS) via superior cervical ganglia (SCG). To study this topic, the concentrations of thyrotropin releasing hormone (THR) and somatostatin (SRIF) were measured in both whole and specific areas of the hypothalamus, as well as plasmatic thyrotropin stimulating hormone (TSH) levels following ablation of SSG. Twenty, forty and fifty days after ablation of SSG, groups of operated and sham-operated animals weighing 230-260 g at the beginning of experimentation, were killed by cervical dislocation. Plasma was taken, frozen and stored for TSH-radioimmunoassay (RIA) and the hypothalami were removed and homogenized in either 0.1 N HCl (for TRH-RIA) or 0.2 N acetic acid (for SRIF-RIA). Twenty days after ablation of SSG in another group, TRH concentrations were measured in both the median eminence (ME) and the paraventricular nucleus (PVN), dissected by the micropunch technique. The results show that twenty days after SSG ablation, the hypothalamic TRH concentrations was significantly lower in operated than in sham-operated animals (295.2 +/- 24.8 vs 226 +/- 11.15 pg/mg hypothalamus respectively p less than 0.01, n = 9). No differences were observed at later intervals. This finding seems to be specific for this peptide since the SRIF level was not modified twenty days after SSG removal. Among the discrete hypothalamic areas examined, only the ME exhibited a significant decrease in TRH content (25.43 +/- 3.02 ng/mg prot. VS. 41.24 +/- 1.33 ng/mg prot., respectively). Despite these results on TRH levels, no modifications in plasmatic TSH levels were observed.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗

PubMed1987

Increase of thyrotropin-releasing hormone immunoreactivity in the nucleus of the solitary tract following bilateral lesions of the hypothalamic paraventricular nuclei.

The effects of bilateral electrolytic lesions of hypothalamic paraventricular nucleus on thyrotropin-releasing hormone (TRH)-immunoreactive fibers of the nucleus of the solitary tract were studied by both immunocytochemistry and radioimmunoassay. Contrasting with a near disappearance of TRH immunoreactivity in the median eminence, both morphological and biochemical approaches demonstrate that such hypothalamic lesions induced significant increase of TRH immunoreactivity in the nucleus of solitary tract. These results confirm that TRH fibers of the nucleus of the solitary tract do not originate in the hypothalamic paraventricular nucleus (PVN). They further indicate that these TRH neurons projecting to the nucleus of the solitary tract are strongly influenced by neurons located within the PVN area.

Animals↗

PubMed1987

Evidence for a dual effect of gamma-aminobutyric acid on thyrotropin (TSH)-releasing hormone-induced TSH release from perifused rat pituitaries.

The effects of gamma-aminobutyric acid (GABA) on the spontaneous and TRH-induced TSH release were investigated in vitro on perifused rat pituitaries. The dynamic pattern of TSH release was measured in response to a 6-min pulse of TRH (10 nM) with or without GABA addition. GABA had no effect on spontaneous TSH release but exhibited a dual effect on TSH-stimulated release according to the dose (as calculated by the induced-basal ratio): a potentiation of the TSH response to TRH at the lowest concentrations tested (less than or equal to 10 nM) and an inhibition for GABA concentrations equal or higher than 100 nM. The GABA potentiation was mimicked by muscimol (10 microM) and isoguvacine (10 nM) but not by baclofen (1 microM). Bicucullin (1 microM) or picrotoxin (1 microM) added 15 min before GABA was unable to reverse the GABA potentiation of the TSH response, although SR 95103 (1 and 10 microM), a specific GABA A antagonist, partially or totally antagonized this response. Diazepam (7 nM) was able to potentiate the TSH response by 216% when GABA was added to the system at a concentration (60 nM) which does not modify by itself the TSH response. The inhibitory effect of GABA (100 nM) was completely abolished by bicucullin (1 microM), by picrotoxin (1 microM), and by SR 95103 (1 microM). Picrotoxin not only blocked the inhibitory action of GABA but significantly (P less than 0.05) potentiated the TSH response to TRH. Our data suggest a dual GABA-ergic control of TRH-stimulated TSH release directly on the pituitary, probably mediated by two different kinds of GABA receptors: a GABA A receptor site mediating the inhibitory effect and a nonclassical GABA A receptor site of higher affinity for its stimulatory action.

Animals↗

PubMed1987

In vitro and in vivo TSH releasing activity of two new analogues of TRH.

The TSH releasing activity of two new analogues of TRH 'Pyr-(N3-Im-methyl)-His-Pro-NH-(n-amyl)' (I) and 'Pyr-His-Pro-(tyramine)' (II) was tested and compared with that of TRH in adult rats to test how structural modifications in the TRH molecule affect its biological activity: 1) in vitro in superfused pituitaries and 2) in vivo after ip injection, with measurement of TSH by RIA before and after addition of each secretagogue. Analogue I was found to be more potent than both TRH itself and Analogue II in stimulating TSH release: at 10 nmol/l in vitro, the ratio of induced to spontaneous release was 4.13 +/- 0.35, 2.98 +/- 0.20, and 1.19 +/- 0.17, respectively for each secretagogue, with a 50% effective dose of 6 X 10(-9) mol/l for Analogue I and 5 X 10(-8) mol/l for TRH. A similar order of potency in increasing plasma TSH (Analogue I greater than TRH greater than Analogue II) was found in vivo, as shown by dose-response curves. After a 4-day pre-treatment with TRH (2 X 100 micrograms/day) a similar TSH response to TRH and Analogue I (500 nmol/kg body weight) was observed. By contrast, the dose of Analogue II needed to obtain the same stimulatory effect on TSH release was twice as high. The biological activity of TRH appears to be more effectively increased by replacing an H atom by an amyl group in the C-terminal amide function of the proline residue of TRH than by a tyramyl group in the same residue.

Animals↗

PubMed1986

Evidence for a role of central type benzodiazepine receptors in the inhibition of the thyrotropin-releasing hormone-induced thyrotropin release from rat perifused pituitaries.

Several centrally active benzodiazepines (BZ) were tested for their ability to inhibit the TRH-induced secretion of TSH in vitro from perifused pituitaries. Diazepam, flurazepam, chlordiazepoxide (CDZ) and midazolam (10 nM) inhibited the TSH response to TRH (10 nM) by 33-50%, while medazepam, a prodrug having virtually no affinity for central BZ sites, did not. CDZ inhibition was reversed by Ro 15-1788, antagonist of the central type BZ binding sites, but not by PK 11195, antagonist of the peripheral type. The data are consistent with an involvement of central type BZ receptor sites in the TSH-lowering effects of BZ in rats.

Animals↗